Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new

被引：67

作者：

Frezza, Anna Maria ^{[1
]}

Stacchiotti, Silvia ^{[1
]}

Gronchi, Alessandro ^{[2
]}

机构：

[1] Fdn IRCCS Ist Nazl Tumori, Dept Canc Med, Milan, Italy

[2] Fdn IRCCS Ist Nazl Tumori, Dept Surg, Via Venezian 1, I-20133 Milan, Italy

来源：

BMC MEDICINE | 2017年 / 15卷

关键词：

Sarcoma; Advanced sarcoma; Metastatic sarcoma; Chemotherapy; Tyrosine kinase inhibitors; VEGF inhibitors; Immunotherapy; Survival; RANDOMIZED PHASE-II; METASTATIC DERMATOFIBROSARCOMA PROTUBERANS; COLLAGEN GENE COL1A1; CASE-SERIES ANALYSIS; B-CHAIN GENE; EUROPEAN-ORGANIZATION; 1ST-LINE TREATMENT; DEDIFFERENTIATED LIPOSARCOMA; ADVANCED ANGIOSARCOMA; IMATINIB MESYLATE;

D O I：

10.1186/s12916-017-0872-y

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

For metastatic soft tissue sarcoma (STS) patients not eligible for surgery, systemic treatments, including standard chemotherapy and newer biological compounds, still play the most relevant role in the management of the disease. An anthracycline and alkylating agent combination has formed the cornerstone of chemotherapy in STS for more than 30 years, with its value over that of administration of anthracycline as a single agent still being debated. Efforts have been made to improve the activity and minimise the toxicity of the combination, as well as to explore the upfront efficacy of agents known to be active in sarcoma and to develop new biological compounds. Nevertheless, beyond the first line, evidence for medical treatment in STS is less robust and all the more driven by histology. Thus, the introduction of kinases and small molecule inhibitors in the treatment armamentarium for STS is a major achievement in this setting. Preliminary data on immunotherapy are also available and discussed in this review.

引用

页数：12

共 94 条

[21] Prognostic Significance of AKT/mTOR and MAPK Pathways and Antitumor Effect of mTOR Inhibitor in NF1-Related and Sporadic Malignant Peripheral Nerve Sheath Tumors [J].

Endo, Makoto ;

Yamamoto, Hidetaka ;

Setsu, Nokitaka ;

Kohashi, Kenichi ;

Takahashi, Yusuke ;

Ishii, Takeaki ;

Iida, Kei-ichiro ;

Matsumoto, Yoshihiro ;

Hakozaki, Michiyuki ;

Aoki, Mikiko ;

Iwasaki, Hiroshi ;

Dobashi, Yoh ;

Nishiyama, Kenichi ;

Iwamoto, Yukihide ;

Oda, Yoshinao .

CLINICAL CANCER RESEARCH, 2013, 19 (02) :450-461

[22]

Fletcher CDM, 2013, WHO CLASSIFICATION T

[23] Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors [J].

Forni, Claudia ;

Minuzzo, Mario ;

Virdis, Emanuela ;

Tamborini, Elena ;

Simone, Matteo ;

Tavecchio, Michele ;

Erba, Eugenio ;

Grosso, Federica ;

Gronchi, Alessandro ;

Aman, Pierre ;

Casali, Paolo ;

D'Incalci, Maurizio ;

Pilotti, Silvana ;

Mantovani, Roberto .

MOLECULAR CANCER THERAPEUTICS, 2009, 8 (02) :449-457

[24]

Fu Y, 2015, INT J CLIN EXP MED, V8, P8288

[25] Randomized Phase II Study Comparing Gemcitabine Plus Dacarbazine Versus Dacarbazine Alone in Patients With Previously Treated Soft Tissue Sarcoma: A Spanish Group for Research on Sarcomas Study [J].

Garcia-del-Muro, Xavier ;

Lopez-Pousa, Antonio ;

Maurel, Joan ;

Martin, Javier ;

Martinez-Trufero, Javier ;

Casado, Antonio ;

Gomez-Espana, Auxiliadora ;

Fra, Joaquin ;

Cruz, Josefina ;

Poveda, Andres ;

Meana, Andres ;

Pericay, Carlos ;

Cubedo, Ricardo ;

Rubio, Jordi ;

De Juan, Ana ;

Lainez, Nuria ;

Antonio Carrasco, Juan ;

de Andres, Raquel ;

Buesa, Jose M. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18) :2528-2533

[26] Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study [J].

Gelderblom, H. ;

Blay, J. Y. ;

Seddon, B. M. ;

Leahy, M. ;

Ray-Coquard, I. ;

Sleijfer, S. ;

Kerst, J. M. ;

Rutkowski, P. ;

Bauer, S. ;

Ouali, M. ;

Marreaud, S. ;

van der Straaten, R. J. H. M. ;

Guchelaar, H-J ;

Weitman, S. D. ;

Hogendoorn, P. C. W. ;

Hohenberger, P. .

EUROPEAN JOURNAL OF CANCER, 2014, 50 (02) :388-396

[27] Phase 2 study of nivolumab in metastatic Ieiomyosarcoma of the uterus. [J].

George, Suzanne ;

Barysauskas, Constance M. ;

Solomon, Sarah ;

Tahlil, Kadija ;

Malley, Rita ;

Hohos, Melissa ;

Polson, Kathleen ;

Loucks, Margaret ;

Wagner, Andrewi. ;

Merriam, Priscilla ;

Morgan, Jeffrey A. ;

Rodig, Scott J. ;

Hodi, F. Stephen ;

Shapiro, Geoffrey ;

Demetri, George D. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

[28] Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas [J].

George, Suzanne ;

Merriam, Priscilla ;

Maki, Robert G. ;

Van den Abbeele, Annick D. ;

Yap, Jeffrey T. ;

Akhurst, Timothy ;

Harmon, David C. ;

Bhuchar, Gauri ;

O'Mara, Margaret M. ;

D'Adamo, David R. ;

Morgan, Jeffrey ;

Schwartz, Gary K. ;

Wagner, Andrew J. ;

Butrynski, James E. ;

Demetri, George D. ;

Keohan, Mary L. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) :3154-3160

[29] Transforming activity of the chimeric sequence formed by the fusion of collagen gene COL1A1 and the platelet derived growth factor b-chain gene in dermatofibrosarcoma protuberans [J].

Greco, A ;

Fusetti, L ;

Villa, R ;

Sozzi, G ;

Minoletti, F ;

Mauri, P ;

Pierotti, MA .

ONCOGENE, 1998, 17 (10) :1313-1319

[30] Primary extremity soft tissue sarcomas: outcome improvement over time at a single institution [J].

Gronchi, A. ;

Miceli, R. ;

Colombo, C. ;

Collini, P. ;

Stacchiotti, S. ;

Olmi, P. ;

Mariani, L. ;

Bertulli, R. ;

Fiore, M. ;

Casali, P. G. .

ANNALS OF ONCOLOGY, 2011, 22 (07) :1675-1681

← 1 2 3 4 5 6 7 8 9 10 →